Clinical Trial Update: DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating DLAAG for acute myeloid leukemia and myelodysplastic syndrome with blast excess, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• DLAAG

Snippet

Sponsor: Shanghai Tong Ren Hospital | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: UNKNOWN